https://scholars.lib.ntu.edu.tw/handle/123456789/495044
標題: | Survival of lung adenocarcinoma patients with malignant pleural effusion | 作者: | SHANG-GIN WU CHONG-JEN YU Tsai M.-F. WEI-YU LIAO CHIH-HSIN YANG I-SHIOW JAN PAN-CHYR YANG JIN-YUAN SHIH |
公開日期: | 2013 | 出版社: | European Respiratory Society | 卷: | 41 | 期: | 6 | 起(迄)頁: | 1409-1418 | 來源出版物: | European Respiratory Journal | 摘要: | In the era of targeted therapy, the association between lung adenocarcinoma patient survival and malignant pleural effusions (MPEs) remains unclear. This study investigated the clinical characteristics, survival and epidermal growth factor receptor (EGFR) gene (EGFR) mutation status of lung adenocarcinoma patients with MPE. From June 2005 to December 2010, consecutive pleural effusions were collected prospectively. Patient clinical characteristics, EGFR mutation status, and overall survival were analysed. We collected MPEs from448 patients in stage IV lung adenocarcinoma at initial diagnosis. Median overall survival for patients with MPEs at initial diagnosis and following disease progression were 14.3 months and 21.4 months, respectively (p=0.001). There were 296 (66.1%) patients harbouring EGFR mutations, the mutation rates among patients with an MPE at initial diagnosis and one following disease progression were 68.2% and 56.6%, respectively (p=0.044); the L858R mutation rate was also higher among the former (32.6% versus 18.1%; p=0.009). Multivariate analysis revealed that patients who: developed MPEs following disease progression, harboured EGFR mutations, and received EGFR-tyrosine kinase inhibitor therapy, had longer overall survival. Patients in stage IV lung adenocarcinoma withMPEs at initial diagnosis have shorter overall survival and higher EGFR mutation rate, especially for L858R, than patients who develop MPEs following disease progression. Copyright?ERS 2013. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84878774987&doi=10.1183%2f09031936.00069812&partnerID=40&md5=09dbdd98b179fcd6c934c6e98b114283 https://scholars.lib.ntu.edu.tw/handle/123456789/495044 |
ISSN: | 0903-1936 | DOI: | 10.1183/09031936.00069812 | SDG/關鍵字: | epidermal growth factor receptor; epidermal growth factor receptor kinase inhibitor; erlotinib; gefitinib; antineoplastic agent; epidermal growth factor receptor; gefitinib; quinazoline derivative; adult; aged; article; cancer staging; cancer survival; clinical feature; disease course; EGFR gene; female; gene mutation; human; human tissue; lung adenocarcinoma; major clinical study; male; overall survival; pleura effusion; priority journal; adenocarcinoma; complication; DNA sequence; exon; genetics; lung tumor; malignant pleura effusion; middle aged; mortality; mutation; prospective study; time; treatment outcome; very elderly; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Prospective Studies; Quinazolines; Receptor, Epidermal Growth Factor; Sequence Analysis, DNA; Time Factors; Treatment Outcome |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。